One of the invited speakers of the Kemomind science conference is Pedro Pinto, PhD researcher from the Cancer Genetics Group,IPO-Porto Research Center, Portugal.
Their short abstract review published online by Cambridge University talking about liquid biopsy. Circulating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called ‘liquid biopsy’, as a non-invasive cancer biomarker has recently received a lot of attention.